Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 1754 |
| INN | Bapineuzumab |
| Status | Terminated |
| Drug code(s) | AAB-001 |
| Brand name | None |
| mAb sequence source | mAb humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | Amyloid beta (N-terminal) |
| Indications of clinical studies | Alzheimer's disease |
| Primary therapeutic area | Neurological disorders |
| Most advanced stage of development (global) | Terminated at Phase 3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | February 15, 2004 |
| Start of Phase 2 | April 15, 2005 |
| Start of Phase 3 | December 15, 2007 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Pfizer |
| Licensee/Partner | None |
| Comments about company or candidate | Fast track. Developed by Wyeth |
| Full address of company | 66 Hudson Boulevard East, New York, NY 10001-2192 USA North America United States of America https://www.pfizer.com/contact |
Target is Amyloid beta N-terminal as per https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772335/
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |